Information Provided By: 
Fly News Breaks for June 25, 2018
RDHL
Jun 25, 2018 | 08:41 EDT
As previously reported, Ladenburg analyst Matthew Kaplan initiated RedHill Biopharma with a Buy rating and $20 price target, citing his focus on the company's portfolio of late-stage compounds. RHB-104, which is being developed for the treatment of Crohn's disease, could generate over $375M in U.S. revenues in 2030 while RHB-105 for the treatment of Helicobacter pylori infection could generate over $350M in peak U.S. revenues for this indication in 2027, Kaplan predicts.
News For RDHL From the Last 2 Days
